Urothelial Bladder Cancer Urinary Biomarkers.
Urothelial bladder cancer is the fourth most prevalent male malignancy in the United States and also one of the ten most lethal. Superficial or non-muscle-invasive bladder cancer has a high rate of recurrence and can progress to muscle invasive disease. Conventional surveillance requires regular cystoscopy and is used often with urinary cytology. Unfortunately, the cystoscopy procedure is invasive for patients and costly for health care providers. Urinary biomarkers have the potential to improve bladder cancer diagnosis, the efficiency and also the cost-effectiveness of follow up. It may also be possible for urinary biomarkers to help prognosticate particularly for patients with high-grade bladder cancer who may want enhanced assessment of their risk of disease progression. In this review the important historical urinary biomarkers and the newly emerging biomarkers are discussed. As will be presented, although many of the tests have good performance characteristics, unfortunately no single test can fulfill all the roles currently provided by cystoscopy and cytology. It is likely that in the future, urinary biomarker testing will be used selectively in a personalized manner to try and improve prognostication or reduce the necessity for invasive cystoscopy in patients understanding the limits of the test.
The University of Toronto, Department of Surgery, Division of Urology, Toronto, Ontario; Princess Margaret Cancer Hospital, Department of Surgical Oncology, Division of Urology, Toronto, Ontario.
Aidan P
AP
Noon
The University of Toronto, Department of Surgery, Division of Urology, Toronto, Ontario; Princess Margaret Cancer Hospital, Department of Surgical Oncology, Division of Urology, Toronto, Ontario; Mount Sinai Hospital, Department of Urology, Department of Surgery, Division of Urology, Toronto, Ontario.
Alexandre R
AR
Zlotta
Biomarker; Bladder; Carcinoma; Urinary; Urothelial
Eur Urol. 2011 Sep;60(3):484-92
21684071
Scand J Clin Lab Invest. 2000 Jul;60(4):275-82
10943597
BJU Int. 2012 Sep;110(5):699-708
22313585
Urol Oncol. 2008 Nov-Dec;26(6):646-51
18367109
Eur Urol. 2010 Jul;58(1):96-104
19674832
Eur Urol. 1999 Jan;35(1):52-6
9933795
World J Urol. 2008 Feb;26(1):59-65
17962949
Am J Pathol. 2012 May;180(5):1808-15
22426337
Clin Chem Lab Med. 2003 Jan;41(1):104-10
12636058
Eur Urol. 2013 Feb;63(2):234-41
22877502
Br J Cancer. 2012 Jun 26;107(1):123-8
22644299
Urology. 2008 Apr;71(4):718-22
18387400
Eur Urol. 2013 Jul;64(1):41-7
23478169
Clin Cancer Res. 2007 Dec 15;13(24):7296-304
18094410
J Urol. 2008 Jun;179(6):2164-9
18423745
Adv Urol. 2011;2011:937561
22162681
J Urol. 2012 Dec;188(6):2101-7
23083854
Clin Cancer Res. 1998 Oct;4(10):2511-20
9796985
Cancer Res. 2013 Dec 15;73(24):7162-7
24121487
World J Urol. 2012 Dec;30(6):869-73
22932760
Urology. 2000 Aug 1;56(2):228-31
10925083
Clin Cancer Res. 2013 Jun 15;19(12):3327
23709676
Cancer. 2011 Jul 1;117(13):2892-7
21692050
Clin Cancer Res. 2005 Nov 1;11(21):7743-8
16278395
J Urol. 1998 Feb;159(2):394-8
9649246
Nat Genet. 2013 Dec;45(12):1459-63
24121792
Eur Urol. 1999 Feb;35(2):89-92
9933800
J Urol. 2002 Nov;168(5):1950-4
12394683
J Urol. 2000 Sep;164(3 Pt 1):634-9
10953114
J Urol. 2013 Mar;189(3):828-33
23017513
Anticancer Res. 1998 Sep-Oct;18(5B):3803-5
9854500
J Urol. 1998 Jun;159(6):1876-80
9598479
J Urol. 2004 Feb;171(2 Pt 1):626-30
14713774
J Urol. 1999 Jul;162(1):53-7
10379739
Urol Oncol. 2010 Nov-Dec;28(6):655-61
19375957
Nat Genet. 2013 Dec;45(12):1464-9
24121791
J Urol. 2010 Jan;183(1):62-7
19913822
Urol Oncol. 2008 May-Jun;26(3):246-9
18452813
J Natl Cancer Inst. 2008 Oct 1;100(19):1401-11
18812553
BJU Int. 2012 Mar;109(6):941-8
21756281
J Urol. 2005 Jul;174(1):64-8
15947579
Anticancer Res. 2012 May;32(5):2015-8
22593481
Adv Urol. 2012;2012:397412
22811704
Can J Urol. 2012 Aug;19(4):6345-50
22892257
Cancer Cytopathol. 2013 Jul;121(7):392-7
23495066
J Urol. 2012 Sep;188(3):741-7
22818138
Eur Urol. 1997;32(4):425-8
9412800
Eur Urol. 2014 Feb;65(2):367-9
24035680
Urol Oncol. 2014 Apr;32(3):222-9
24054865
Eur Urol. 2011 May;59(5):671-81
21296484
Urology. 1997 Dec;50(6):882-7
9426718
Asian J Androl. 2007 Sep;9(5):711-5
17712491
Int J Urol. 1999 Apr;6(4):173-7
10226833
J Urol. 1996 Aug;156(2 Pt 1):363-7
8683680
J Urol. 2003 Jun;169(6):2101-5
12771727
Scand J Urol Nephrol. 2001 Sep;35(4):280-2
11676352
Nat Genet. 2013 Dec;45(12):1428-30
24121789
Urology. 1998 Sep;52(3):398-402
9730450
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
22237781
Anticancer Res. 2012 Nov;32(11):5093-7
23155286
Nat Rev Urol. 2013 Dec;10(12):675
24189933
Eur Urol. 2014 Feb;65(2):360-6
24018021
JAMA. 2001 Jan 17;285(3):324-8
11176843
Occup Environ Med. 2012 Apr;69(4):300-1
22068171
Clin Cancer Res. 2013 Apr 1;19(7):1717-28
23403633
PLoS One. 2012;7(4):e35363
22530010
Urol Clin North Am. 2000 Feb;27(1):63-73, ix
10696246
Clin Chem. 1999 Apr;45(4):472-7
10102906
Clin Cancer Res. 2004 Nov 15;10(22):7457-65
15569975
Eur Urol. 1999 Jan;35(1):81-7
9933798
Clin Cancer Res. 2010 Jun 1;16(11):3011-8
20404005
World J Urol. 2010 Jun;28(3):399-404
20309562
J Urol. 1999 May;161(5):1486-9
10210378
Eur Urol. 2013 May;63(5):936-40
22521093
Clin Cancer Res. 2013 Sep 1;19(17):4760-9
23842048
Urology. 2003 Dec;62(6):1134-8
14665377
Diagn Cytopathol. 1999 May;20(5):285-90
10319229
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1483-91
21586619
J Urol. 1999 Feb;161(2):388-94
9915409
Clin Cancer Res. 2010 May 1;16(9):2624-33
20406841
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):28-32
22630336
Urology. 2013 Nov;82(5):1059-64
24044907
Urology. 2004 Dec;64(6):1121-6
15596183